Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The document serves as a notification of a transaction involving a Connected Person rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of 1752.133 pence per Ordinary Share at the time of a specific transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a minor acquisition of 10 Ordinary Shares by Mrs. K Thomson, a Connected Person, resulting from the reinvestment of dividends under the GlaxoSmithKline ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a director-related transaction.
Key Facts for Investors to Verify
- This filing reports a routine dividend reinvestment transaction for a Connected Person, not a corporate event.
- The transaction involved the acquisition of 10 Ordinary Shares at 1752.133 pence per share on July 11, 2013.
- Investors should refer to the company's Form 20-F or quarterly earnings releases for comprehensive financial performance data.